Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Baxter
Johnson and Johnson
Medtronic

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,174,524

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,174,524 protect, and when does it expire?

Patent 6,174,524 protects TIMOLOL MALEATE and is included in one NDA.

Protection for TIMOLOL MALEATE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-one patent family members in eighteen countries.

Summary for Patent: 6,174,524
Title: Gelling ophthalmic compositions containing xanthan gum
Abstract:Ophthalmic drug delivery vehicles which are administrable as a liquid and which gel upon contact with the eyes are disclosed. The vehicles contain xanthan gum.
Inventor(s): Bawa; Rajan (Fort Collins, CO), Hall; Rex E. (Fort Worth, TX), Kabra; Bhagwati P. (Arlington, TX), Teague; James E. (Arlington, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Application Number:09/277,102
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 6,174,524

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sandoz Inc TIMOLOL MALEATE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020963-001 Oct 21, 1998 AB RX No No   Start Trial   Start Trial Y   Start Trial
Sandoz Inc TIMOLOL MALEATE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020963-002 Oct 21, 1998 AB RX No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,174,524

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016460   Start Trial
Austria 245451   Start Trial
Australia 3194799   Start Trial
Australia 740586   Start Trial
Brazil 9910113   Start Trial
Canada 2322579   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
Johnson and Johnson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.